169 related articles for article (PubMed ID: 31105026)
1. Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
J Pharmacol Sci; 2019 May; 140(1):20-25. PubMed ID: 31105026
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
Eur J Clin Pharmacol; 2019 Apr; 75(4):529-542. PubMed ID: 30610273
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
Deyme L; Barbolosi D; Mbatchi LC; Tubiana-Mathieu N; Ychou M; Evrard A; Gattacceca F
Cancer Chemother Pharmacol; 2021 Aug; 88(2):247-258. PubMed ID: 33912999
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
5. [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].
Song Y; Li WW; Huang J
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):380-383. PubMed ID: 28535657
[No Abstract] [Full Text] [Related]
6. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
8. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Roncato R; Cecchin E; Montico M; De Mattia E; Giodini L; Buonadonna A; Solfrini V; Innocenti F; Toffoli G
Clin Pharmacol Ther; 2017 Jul; 102(1):123-130. PubMed ID: 28074472
[TBL] [Abstract][Full Text] [Related]
9. A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.
Tobin PJ; Beale P; Noney L; Liddell S; Rivory LP; Clarke S
Cancer Chemother Pharmacol; 2006 Feb; 57(3):309-16. PubMed ID: 16003560
[TBL] [Abstract][Full Text] [Related]
10. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Martinez J; Martin C; Chacon M; Korbenfeld E; Bella S; Senna S; Richardet E; Coppola F; Bas C; Hidalgo J; Escobar E; Reale M; Smilovich AM; Wasserman E
Am J Clin Oncol; 2006 Feb; 29(1):45-51. PubMed ID: 16462502
[TBL] [Abstract][Full Text] [Related]
13. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
[TBL] [Abstract][Full Text] [Related]
14. A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Kalofonos HP; Skarlos D; Bafaloukos D; Papakostas P; Bamias A; Janinis J; Timotheadou E; Kouvatseas G; Stavropoulos M; Economopulos T; Fountzilas G
Cancer Invest; 2003; 21(6):855-62. PubMed ID: 14735689
[TBL] [Abstract][Full Text] [Related]
15. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Stickel F; Jüngert B; Brueckl V; Schirner I; Brueckl WM; Männlein G; Hegewald J; Mühldorfer S; Bittorf B; Hohenberger W; Hahn EG; Wein A
Anticancer Drugs; 2003 Oct; 14(9):745-9. PubMed ID: 14551509
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Saltz LB; Kanowitz J; Kemeny NE; Schaaf L; Spriggs D; Staton BA; Berkery R; Steger C; Eng M; Dietz A; Locker P; Kelsen DP
J Clin Oncol; 1996 Nov; 14(11):2959-67. PubMed ID: 8918493
[TBL] [Abstract][Full Text] [Related]
17. Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Tsavaris N; Ziras N; Kosmas C; Giannakakis T; Gouveris P; Vadiaka M; Dimitrakopoulos A; Karadima D; Rokana S; Papalambros E; Papastratis G; Margaris H; Tsipras H; Polyzos A
Cancer Chemother Pharmacol; 2003 Dec; 52(6):514-9. PubMed ID: 14504920
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
19. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
McWilliams RR; Goetz MP; Morlan BW; Salim M; Rowland KM; Krook JE; Ames MM; Erlichman C
Clin Colorectal Cancer; 2007 May; 6(7):516-21. PubMed ID: 17553200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]